


Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

Listing of the Claims:

1-16. (Cancelled).

17. (Currently Amended) A compound of formula (I),



the *N*-oxide forms, the addition salts and the stereo-chemically isomeric forms thereof,
wherein

n is 0, 1 or 2;

X is N or CR⁷, wherein R⁷ is hydrogen or taken together with R¹ may form a bivalent
radical of formula -CH=CH-CH=CH-;

R¹ is C₁₋₆alkyl or thiophenyl;

R² is hydrogen, hydroxy, C₁₋₆alkyl, or C₃₋₆alkynyl or taken together with R³ may form
=O;

except that when X is N, R² together with R³ cannot form =O;

R³ is a radical selected from

-(CH₂)_s- NR⁸R⁹ (a-1),

-O-H (a-2),

-O-R¹⁰ (a-3),

-S- R¹¹ (a-4), or

—C≡N (a-5),

wherein

s is 0, 1, 2 or 3;

R⁸, R¹⁰ and R¹¹ are each independently selected from -CHO, C₁₋₆alkyl,

hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyl, amino, C₁₋₆alkylamino,
 di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonylaminoC₁₋₆alkyl,
 piperidinyC₁₋₆alkylaminocarbonyl, piperidiny, piperidinyC₁₋₆alkyl,
 piperidinyC₁₋₆alkylaminocarbonyl, C₁₋₆alkyloxy, thiophenylC₁₋₆alkyl,
 pyrrolylC₁₋₆alkyl, arylC₁₋₆alkylpiperidiny, arylcarbonylC₁₋₆alkyl,
 arylcarbonylpiperidinyC₁₋₆alkyl, haloindozolylpiperidinyC₁₋₆alkyl,
 arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, and

R⁹ is hydrogen or C₁₋₆alkyl;










or R³ is a group of formula




wherein

t is 0, 1, 2 or 3;

-Z is a heterocyclic ring system selected from



wherein R^{12} is hydrogen, halo, C_{1-6} alkyl, aminocarbonyl, amino, hydroxy, aryl,




C_{1-6} alkylamino C_{1-6} alkyloxy, C_{1-6} alkyloxy C_{1-6} alkyl, C_{1-6} alkyloxy C_{1-6} alkylamino, aryl C_{1-6} alkyl, di(phenyl C_{2-6} alkenyl), piperidinyl, piperidinyl C_{1-6} alkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl C_{1-6} alkyl, aryloxy(hydroxy) C_{1-6} alkyl, haloindazolyl, aryl C_{1-6} alkyl, aryl C_{2-6} alkenyl, aryl C_{1-6} alkylamino, morpholino, C_{1-6} alkylimidazolyl, pyridinyl C_{1-6} alkylamino; and

R^{13} is hydrogen, piperidinyl or aryl;

R^4 , R^5 and R^6 are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C_{1-6} alkyl, C_{1-6} alkyloxy, amino, amino C_{1-6} alkyl, di(C_{1-6} alkyl)amino, di(C_{1-6} alkyl)amino C_{1-6} alkyloxy or C_{1-6} alkyloxycarbonyl, or C_{1-6} alkyl substituted with 1, 2 or 3 substituents independently selected from hydroxy, C_{1-6} alkyloxy, or amino C_{1-6} alkyloxy; or

when R^5 and R^6 are on adjacent positions they may taken together form a bivalent radical of formula




wherein R^{14} is C_{1-6} alkyl;

and aryl is phenyl, phenyl substituted with halo, C_{1-6} alkyl or C_{1-6} alkyloxy.

18. (Currently Amended) A compound as claimed in claim 17 wherein


~~R^1 is C_{1-6} alkyl;~~ R^3 is a radical selected from the group consisting of (a-1), (a-2), (a-3) (a-5), and (b-1) wherein -Z is a heterocyclic ring system selected from (c-1), (c-6), (c-8), (c-9), or (c-11); s is 0, 1 or 2; R^8 and R^{10} are each independently selected from -CHO, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, di(C_{1-6} alkyl)amino C_{1-6} alkyl, C_{1-6} alkylcarbonylamino C_{1-6} alkyl, piperidinyl C_{1-6} alkyl,

piperidinylC₁₋₆alkylaminocarbonyl, C₁₋₆alkyloxy, thiophenylC₁₋₆alkyl, pyrrolylC₁₋₆alkyl, arylC₁₋₆alkylpiperidinyl, arylcarbonylC₁₋₆alkyl, arylcarbonylpiperidinylC₁₋₆alkyl, haloindozolylpiperidinylC₁₋₆alkyl, or arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl; t is 0 or 2; R¹² is hydrogen,




C₁₋₆alkyl, aminocarbonyl, C₁₋₆alkyloxyC₁₋₆alkylamino, di(phenylC₂₋₆alkenyl), piperidinylC₁₋₆alkyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylC₁₋₆alkyl, haloindazolyl, or arylC₂₋₆alkenyl; R⁴, R⁵ and R⁶ are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C₁₋₆alkyl, C₁₋₆alkyloxy, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy or C₁₋₆alkyloxycarbonyl; and when R⁵ and R⁶ are on adjacent positions they may taken together form a bivalent radical of formula (d-1) or (d-2).


19. (Currently Amended) A compound according to claim 17 wherein n is 0; X is CH; ~~R¹ is C₁₋₆alkyl~~; R² is hydrogen; ~~wherein~~ -Z is a heterocyclic ring system selected from (c-1); t is 2; R¹² is hydrogen; R¹³ is hydrogen; and R⁵ and R⁶ are on adjacent positions and taken together form a bivalent radical of formula (d-2).
20. (Currently Amended) A compound selected from the group consisting of compounds No 16, compound No 144, and compound No. 145:



compound 16



Compound 144



Compound 145

21. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 17.

22. (Cancelled).